Results 61 to 70 of about 5,934 (217)
Effects of hallucinogenic drugs on the human heart
Frontiers in PharmacologyHallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT2A-serotonin receptors in the brain.
Joachim Neumann +4 more
doaj +1 more source
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Frontiers in Psychiatry, 2020 Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders.
Juan José Fuentes +10 more
doaj +1 more source
Safety pharmacology of acute mescaline administration in healthy participants
British Journal of Clinical Pharmacology, EarlyView.Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber +4 more
wiley +1 more source
A mood disorder episode with an onset under chronic cannabis consumption and accompanied with psychotic features immediately after N, N-Dimethyltryptamine (DMT) use: a case report [PDF]
Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi, 2011 , N-dimethyltryptamine (DMT) is a serotonin agonist hallucinogen, similar to lysergic acid diethylamide (LSD). Syntetic production of DMT as well as extraction from several plants of South American flora is possible.
Güliz Özgen +3 more
doaj
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli +8 more
wiley +1 more source
Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada
Addiction, Volume 121, Issue 7, Page 1781-1793, July 2026.Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran +9 more
wiley +1 more source
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
The paradoxical psychological effects of lysergic acid diethylamide (LSD)
, 2016 Background: Lysergic acid diethylamide (LSD) is a potent serotonergic hallucinogen or psychedelic that modulates consciousness in a marked and novel way.
Feilding, A. +15 more
core +2 more sources
CorticaDans ce travail, l’objectif principal est d’explorer les effets et l’efficacité du diéthylamide de l'acide lysergique, plus communément connu sous le nom de LSD, dans le traitement du trouble lié à l’usage de l’alcool.
Maya Oberson
doaj +1 more source
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Frontiers in Psychiatry, 2020 The efficacy of psychedelic-assisted therapies for mental disorders has been attributed to the lasting change from experiential avoidance to acceptance that these treatments appear to facilitate.
Max Wolff +8 more
doaj +1 more source